ACRS
Aclaris Therapeutics, Inc.
There isn't enough reported data to score ACRS yet.
HIMS
Hims & Hers Health, Inc.
There isn't enough reported data to score HIMS yet.
ACRS Fundamentals
| Metric | Status |
|---|---|
| Weak | |
| Weak | |
| Weak | |
| Unavailable |
ACRS's revenue, profitability and cash flow are currently weak. There isn't enough data to rate its balance sheet.
HIMS Fundamentals
| Metric | Status |
|---|---|
| Strong | |
| Weak | |
| Stable | |
| Strong |
HIMS's revenue and balance sheet are currently strong, and its cash flow is stable, but its profitability is weak.
ACRS PE Valuation
ACRS has no meaningful PE right now: it lost money over the past year.
HIMS PE Valuation
HIMS has no meaningful PE right now: it lost money over the past year.
ACRS Forward outlook
| Metric | Outlook |
|---|---|
| -- | |
| Losses steady | |
| Decline | |
| -- | |
| Limited | |
| Low |
Analysts expect ACRS's revenue to decline, with its earnings and profitability holding steady. However, they disagree widely on these estimates.
HIMS Forward outlook
| Metric | Outlook |
|---|---|
| -- | |
| Turning to a loss | |
| Strong growth | |
| Stable | |
| Limited | |
| Low |
Analysts expect HIMS's revenue to grow, but its earnings to decline. However, they disagree widely on these estimates.
ACRS Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Q3 2026 | -$0.58 | +$1.00 |
| Q2 2026 | -$0.58 | +$0.99 |
| Q1 2026 | -$0.56 | +$1.03 |
| Q4 2025 | -$0.53 | +$1.18 |
| Q3 2025 | -$1.58 | -$1.06 |
| Q2 2025 | -$1.57 | -$0.75 |
| Q1 2025 | -$1.59 | -$0.50 |
| Q4 2024 | -$1.71 | -$0.44 |
ACRS is still losing money, but far less than before: $0.58 per share over the past year, against $3.90 at its worst in late 2019.
HIMS Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Q3 2026 | -$0.83 | -257% |
| Q2 2026 | -$0.63 | -180% |
| Q1 2026 | -$0.09 | -113% |
| Q4 2025 | $0.51 | -3.8% |
| Q3 2025 | $0.53 | +20% |
| Q2 2025 | $0.79 | +888% |
| Q1 2025 | $0.68 | +$0.69 |
| Q4 2024 | $0.53 | +$0.64 |
HIMS has swung to a loss: it lost $0.83 per share over the past year, after a profit the year before.
ACRS Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $1.5M | -55% |
| Q2 2026 | $1.6M | -8.3% |
| Q1 2026 | $2M | +37% |
| Q4 2025 | $1.3M | -86% |
| Q3 2025 | $3.3M | -24% |
| Q2 2025 | $1.8M | -36% |
| Q1 2025 | $1.5M | -39% |
| Q4 2024 | $9.2M | -48% |
ACRS's revenue has slid since its 2022 peak: $1M last quarter, down 55% from the same quarter a year ago.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | -1441% | -921 points |
| Q2 2026 | -1488% | -452 points |
| Q1 2026 | -1112% | +131 points |
| Q4 2025 | -1756% | -673 points |
| Q3 2025 | -520% | -279 points |
| Q2 2025 | -1036% | -571 points |
| Q1 2025 | -1243% | -453 points |
| Q4 2024 | -1082% | -1059 points |
ACRS's operating margin was −1441% last quarter, down 921 points from the same quarter a year ago.
HIMS Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $890.4M | +49% |
| Q2 2026 | $753.2M | +38% |
| Q1 2026 | $608.1M | +3.8% |
| Q4 2025 | $617.8M | +28% |
| Q3 2025 | $599M | +49% |
| Q2 2025 | $544.8M | +73% |
| Q1 2025 | $586M | +111% |
| Q4 2024 | $481.1M | +95% |
HIMS has the edge over ACRS on sales, with more consistent year-over-year improvement.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | -7.4% | -9.4 points |
| Q2 2026 | -13% | -18 points |
| Q1 2026 | -13% | -23 points |
| Q4 2025 | 1.5% | -2.4 points |
| Q3 2025 | 2% | -3.6 points |
| Q2 2025 | 4.9% | +1.4 points |
| Q1 2025 | 9.9% | +6.3 points |
| Q4 2024 | 3.9% | +4 points |
HIMS has the edge over ACRS on profitability, with a higher operating margin.
ACRS Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | -$24.1M | -$13.1M |
| Q2 2026 | -$19.9M | -$9.9M |
| Q1 2026 | -$18.2M | -$5.1M |
| Q4 2025 | -$13.2M | -$4.2M |
| Q3 2025 | -$11M | -150% |
| Q2 2025 | -$10M | +$2.3M |
| Q1 2025 | -$13.1M | +$7.9M |
| Q4 2024 | -$8.9M | -$1.7M |
ACRS has burned cash in almost every quarter: −$75M over the past year, against −$43M the year before.
HIMS Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | $26M | -67% |
| Q2 2026 | -$68.2M | +$1.3M |
| Q1 2026 | $53.1M | +5.9% |
| Q3 2025 | $79.3M | -7% |
| Q2 2025 | -$69.5M | -230% |
| Q1 2025 | $50.1M | +94% |
| Q3 2024 | $85.3M | +238% |
| Q2 2024 | $53.6M | +219% |
HIMS has the edge over ACRS on cash generation, producing positive trailing cash flow while its opponent burns cash.
ACRS Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +4.7% | +6.7M shares |
| 1 year | +22% | +26.8M shares |
| 3 years | +112% | +78.8M shares |
| 5 years | +177% | +95.5M shares |
| Available history | +262% | +108M shares |
ACRS has 149M diluted shares, up 22% from a year ago.
HIMS Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +0.9% | +2.1M shares |
| 1 year | -6% | -14.9M shares |
| 3 years | +11% | +23.7M shares |
| 5 years | +17% | +33.8M shares |
HIMS has the edge over ACRS on shareholder dilution, with a more favorable share count trend.
| Quarter | Spent |
|---|---|
| Q4 2025 | $80.5M |
| Q3 2025 | $9.5M |
| Q2 2025 | — |
| Q1 2025 | — |
| Q4 2024 | $5M |
| Q3 2024 | $30M |
| Q2 2024 | $19.9M |
| Q1 2024 | $28.1M |
ACRS Net Leverage
ACRS's operating earnings (EBITDA) were negative over the past year, so its debt can't be measured against them.
HIMS Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q1 2026 | -5.9x | Net Cash |
| Q4 2025 | -1.4x | Net Cash |
| Q3 2025 | -2.2x | Net Cash |
| Q2 2025 | -7.3x | Net Cash |
| Q1 2025 | -2.1x | Net Cash |
| Q4 2024 | -2.8x | Net Cash |
| Q3 2024 | -2.9x | Net Cash |
| Q2 2024 | -5.5x | Net Cash |
HIMS has more cash than debt.
ACRS Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 43.9 | Neutral |
| Stochastic | 22.7 | Neutral |
ACRS's weekly RSI is 44 (neutral) and its Stochastic is 23 (neutral).
HIMS Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 36.0 | Neutral |
| Stochastic | 23.0 | Neutral |
HIMS's weekly RSI is 36 (neutral) and its Stochastic is 23 (neutral).
ACRS PE vs Healthcare Sector
ACRS has no meaningful PE right now: it lost money over the past year.
HIMS PE vs Healthcare Sector
| Metric | HIMS | Sector median | Relative |
|---|---|---|---|
| PE | N/A | 26x | — |
HIMS has no meaningful PE right now: it lost money over the past year.
ACRS Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $4.03 | 0.7% below |
| 20 week MA | $5.03 | 20% below |
| 50 week MA | $4.27 | 6.3% below |
| 100 week MA | $3.09 | 29% above |
| 200 week MA | $3.91 | 2.3% above |
ACRS has the edge over HIMS on trend strength, trading above more of its moving averages.
HIMS Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $27.3 | 28% below |
| 20 week MA | $29.2 | 32% below |
| 50 week MA | $27.7 | 29% below |
| 100 week MA | $35.9 | 45% below |
| 200 week MA | $24.4 | 19% below |
HIMS is in a downtrend: it's below all five of its weekly moving averages, and 19% below its 200-week average.
ACRS Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $1.92 | $7.61 | +296% |
| 2021 | $7.61 | $15.4 | +103% |
| 2022 | $15.4 | $15.1 | -2.3% |
| 2023 | $15.1 | $1.05 | -93% |
| 2024 | $1.05 | $2.73 | +160% |
| 2025 | $2.73 | $3.03 | +11% |
| 2026 YTD | $3.03 | $4.00 | +32% |
ACRS has the edge over HIMS on returns for 2026, with the stronger performance.
HIMS Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $9.89 | $15.0 | +51% |
| 2021 | $15.0 | $6.65 | -56% |
| 2022 | $6.65 | $6.43 | -3.3% |
| 2023 | $6.43 | $8.90 | +38% |
| 2024 | $8.90 | $26.6 | +198% |
| 2025 | $26.6 | $34.3 | +29% |
| 2026 YTD | $34.3 | $19.7 | -42% |
HIMS's yearly returns have swung widely, from +198% in 2024 to −56% in 2021. It's down 42% so far in 2026.